GPM Reminds Investors of the October 3rd Deadline in the Class Action Lawsuit Against Keryx Pharmaceuticals, Inc. & Encourage...
September 20 2016 - 11:38AM
Business Wire
Investors with losses of $50,000 of more are encouraged to
contact the firm to discuss their legal rights.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the
October 3, 2016 deadline to file a lead plaintiff motion in
the class action lawsuit filed on behalf of investors who purchased
or otherwise acquired Keryx Pharmaceuticals, Inc. ("Keryx" or the
"Company") (NASDAQ: KERX) securities between September 2, 2013,
and August 1, 2016, inclusive (the “Class Period”). Keryx
investors have October 3, 2016 to file a lead plaintiff
motion.
The complaint filed in this lawsuit alleges that
throughout the Class Period, Defendants made materially false
and/or misleading statements, and/or failed to disclose: (1) that
the Company was experiencing production-related difficulties in
converting API to finished drug product; (2) that the issue was
resulting in decreased production yields of finished drug product;
(3) that, as a result, the Company would, and did exhaust its
reserve of finished drug product; and (4) that, as a result of the
foregoing, Defendants’ statements about Keryx’s business,
operations, and prospects, were false and misleading and/or lacked
a reasonable basis.
If you purchased or otherwise acquired Keryx shares during the
Class Period, you may move the Court no later than October
3, 2016 to request appointment as lead plaintiff. To be a
member of the class you need not take any action at this time; you
may retain counsel of your choice or take no action and remain an
absent member of the Class. If you wish to learn
more about this action, or if you have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire,
of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California
90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160920006457/en/
Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024